Symptomatology and General Principles of Treatment of Chronic Hepatitis, Liver Cirrhosis and Chronic Pancreatitis
1. Kebekova Aizat Ashimzhanovna
2. Faizan Mohd
3. Yadav Yogesh
(1. Lecturer, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
3. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic)
Abstract
Background: Chronic hepatitis, liver cirrhosis and chronic pancreatitis are important chronic disorders of the digestive system. They differ in their primary pathology but may cause progressive fibrosis, impaired organ function, nutritional abnormalities and life-threatening complications.
Objective: To summarize the etiology, pathogenesis, symptomatology, diagnostic evaluation, complications and general principles of treatment of chronic hepatitis, liver cirrhosis and chronic pancreatitis.
Methods: This narrative clinical review synthesizes established clinical knowledge and selected contemporary guidance from the World Health Organization (WHO), the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), and the European Association for the Study of the Liver (EASL). It is not a systematic review; no reproducible database search, formal screening, risk-of-bias assessment or quantitative synthesis was performed.
Results: Chronic hepatitis may be asymptomatic or cause fatigue, anorexia, nausea, right upper-quadrant discomfort, jaundice and biochemical abnormalities. Persistent hepatic injury can lead to fibrosis and cirrhosis. Cirrhosis is characterized by fibrosis, regenerative nodules, portal hypertension and impaired hepatic function; decompensation may present with ascites, variceal bleeding or hepatic encephalopathy. Chronic pancreatitis is a fibroinflammatory disease associated with abdominal pain, exocrine pancreatic insufficiency, malnutrition and diabetes. Management is directed toward the underlying cause, prevention of further injury, symptom control, nutritional support and treatment or prevention of complications.
Conclusion: Early etiological diagnosis, appropriate disease-directed treatment, monitoring and complication prevention are central to care. Treatment must be individualized according to disease cause, severity, comorbidities and current specialist guidance.
Keywords: chronic hepatitis; cirrhosis; chronic pancreatitis; portal hypertension; ascites; hepatic encephalopathy; pancreatic insufficiency.
1. Introduction
The liver and pancreas are essential organs involved in metabolism, digestion, detoxification, protein synthesis, glucose regulation and homeostasis. Chronic disorders of these organs can have systemic consequences.
Chronic hepatitis is a persistent inflammatory liver disorder that may arise from viral infection, autoimmune disease, metabolic dysfunction, alcohol-associated liver disease or drug-induced injury. Continued hepatocellular injury can cause fibrosis and, in some patients, cirrhosis.
Cirrhosis is advanced chronic liver disease characterized by fibrosis and regenerative nodules that distort hepatic architecture. This distortion increases intrahepatic vascular resistance and may impair hepatic synthetic, metabolic and detoxifying functions. Portal hypertension and hepatic insufficiency can produce ascites, variceal hemorrhage, encephalopathy and other complications.
Chronic pancreatitis is a persistent fibroinflammatory disorder associated with irreversible structural pancreatic damage and variable exocrine and endocrine dysfunction. Alcohol exposure, tobacco smoking, genetic susceptibility, recurrent acute pancreatitis and ductal abnormalities are recognized contributors.¹
These conditions may be clinically silent in early stages. Their manifestations range from nonspecific fatigue or abdominal discomfort to jaundice, gastrointestinal bleeding, severe malnutrition and organ failure. Care requires an integrated approach involving diagnosis, etiological treatment, symptom management, nutrition, surveillance and long-term follow-up.
2. Objectives
Primary objective:
To describe the symptomatology and general principles of treatment of chronic hepatitis, liver cirrhosis and chronic pancreatitis.
Secondary objectives:
1. Describe major causes and mechanisms of disease.
2. Summarize characteristic clinical manifestations.
3. Outline diagnostic investigations and severity assessment.
4. Discuss major complications.
5. Present general principles of treatment and prevention.
6. Identify situations requiring urgent evaluation or specialist care.
3. Materials and methods
This article is a narrative clinical review. It summarizes established clinical concepts and selected authoritative guidance relevant to chronic hepatitis, cirrhosis and chronic pancreatitis. Sources include WHO guidance on chronic hepatitis B, AASLD/IDSA guidance on hepatitis C, AASLD guidance on portal hypertension and ascites, AGA clinical practice advice on ascites, AASLD guidance on hepatocellular carcinoma (HCC), EASL guidance, and the ACG clinical guideline on chronic pancreatitis.
The review was organized by disease and emphasizes symptomatology, diagnostic evaluation, treatment principles and complication prevention. It is not a systematic review or meta-analysis. No formal reproducible search strategy, independent screening, study selection flow, evidence grading or risk-of-bias assessment was performed. Recommendations are summarized for education and should be checked against current local guidance and individual patient circumstances.
4. Chronic Hepatitis
4.1 Definition
Chronic hepatitis refers to persistent hepatic inflammation and injury. In many clinical contexts, chronicity is defined by persistence for at least six months, but the precise definition and evaluation depend on the etiology. The condition may remain stable, improve, or progress to fibrosis and cirrhosis.
4.2 Etiology and classification
Major causes include:
· Chronic hepatitis B virus (HBV) infection.
· Chronic hepatitis C virus (HCV) infection.
· Hepatitis D virus (HDV) infection in the presence of HBV.
· Autoimmune hepatitis.
· Alcohol-associated liver disease.
· Metabolic dysfunction-associated steatotic liver disease (MASLD), including steatohepatitis.
· Drug- or supplement-induced liver injury.
· Less common genetic, metabolic or cholestatic disorders.
Alcohol-associated hepatitis is a specific clinical syndrome and should not be used as a synonym for all chronic alcohol-associated liver injury. Similarly, MASLD and its inflammatory form are distinct from viral or autoimmune chronic hepatitis, although all can cause fibrosis.
4.3 Pathogenesis
Persistent hepatocellular injury activates inflammatory pathways and hepatic stellate cells. Activated stellate cells acquire a myofibroblast-like phenotype and produce extracellular matrix, including collagen. With continuing injury, matrix accumulation may cause fibrosis and architectural distortion. Advanced fibrosis may progress to cirrhosis, but progression is variable and depends on etiology, disease activity, treatment and host factors.
4.4 Symptomatology
Chronic hepatitis may be asymptomatic and detected during routine laboratory testing. When symptoms occur, they may include:
General symptoms:
· Fatigue and weakness.
· Malaise and reduced exercise tolerance.
· Loss of appetite.
· Nausea, occasional vomiting or weight loss.
Abdominal symptoms:
· Dyspepsia or nonspecific abdominal discomfort.
· Right upper-quadrant pain or heaviness.
· Hepatomegaly or mild hepatic tenderness in some patients.
Hepatobiliary manifestations:
· Jaundice.
· Dark urine or pale stools when cholestasis is present.
· Pruritus, particularly in cholestatic disease.
Extrahepatic manifestations:
Selected etiologies, especially viral or autoimmune disease, may be associated with arthralgia, skin manifestations, renal involvement, vasculitic features or other systemic findings.
Symptoms and examination findings do not reliably determine fibrosis stage. Significant fibrosis may be present even when symptoms are mild and aminotransferase elevations are modest.
4.5 Physical examination
Assessment should include general condition, nutritional status and signs of chronic liver disease.
General examination may reveal pallor, jaundice, muscle wasting, weight loss, peripheral edema or scratch marks. Abdominal examination should assess liver size and consistency, tenderness, splenomegaly, abdominal distension, ascites and collateral veins.
Splenomegaly, ascites, abdominal wall collaterals, thrombocytopenia, asterixis or altered mental status raise concern for advanced disease or portal hypertension and warrant further evaluation.
4.6 Diagnostic investigations
The evaluation aims to identify the cause, assess injury and synthetic function, estimate fibrosis and detect complications.
Laboratory tests:
· ALT and AST: markers of hepatocellular injury, not direct measures of hepatic functional reserve.
· Alkaline phosphatase and GGT: help assess cholestatic patterns.
· Total and direct bilirubin: evaluate bilirubin handling.
· Albumin and PT/INR: contribute to assessment of synthetic function, though each can be affected by nonhepatic factors.
· CBC: may identify anemia, leukopenia or thrombocytopenia.
· Creatinine and electrolytes: assess renal function and metabolic complications.
Viral evaluation, according to clinical context:
· HBsAg, anti-HBc and anti-HBs.
· HBeAg/anti-HBe and HBV DNA when indicated.
· Anti-HCV followed by HCV RNA to establish current infection.
· HDV antibody and HDV RNA when indicated.
A positive anti-HCV antibody alone does not establish current viremia; HCV RNA testing is required to confirm active infection.
Autoimmune evaluation may include ANA, anti-smooth-muscle antibody, serum IgG and other tests selected according to the clinical presentation. Diagnosis requires integration of clinical, serological and sometimes histological findings.
Imaging:
· Ultrasound evaluates liver morphology, biliary abnormalities, spleen, ascites and features suggestive of advanced disease.
· Elastography estimates liver stiffness and may help assess fibrosis.
· CT or MRI is used when further anatomical assessment or evaluation of a focal lesion is required.
Liver biopsy is reserved for selected cases when diagnosis remains uncertain, histology is likely to alter management, or noninvasive assessment is inconclusive. It is not required in every patient.
4.7 General principles of treatment
Treatment depends on the cause and stage. General measures include:
1. Avoid alcohol when liver disease is present; abstinence is particularly important in alcohol-associated disease.
2. Review prescription medicines, over-the-counter drugs, herbal products and supplements for potential hepatotoxicity.
3. Maintain adequate nutrition and a healthy weight.
4. Manage diabetes, dyslipidemia and other metabolic risks.
5. Vaccinate against hepatitis A and B when indicated and not immune.
6. Counsel about transmission prevention for viral hepatitis.
7. Monitor liver injury, fibrosis and complications according to the underlying disease.
Chronic hepatitis B:
The objectives are to suppress HBV replication, reduce hepatic inflammation and lower the risk of cirrhosis and HCC. WHO’s 2024 guidance broadened and simplified treatment eligibility, including treatment for specified patients with significant fibrosis or cirrhosis irrespective of ALT or HBV DNA thresholds.³ Common high-barrier agents include tenofovir disoproxil fumarate, tenofovir alafenamide and entecavir. Selection and monitoring depend on renal function, bone health, pregnancy considerations, previous treatment and availability. Therapy often requires long-term follow-up; patients should not stop treatment without clinician supervision.
Chronic hepatitis C:
Direct-acting antiviral (DAA) regimens target viral proteins and cure most appropriately treated patients. Common regimens include sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. Regimen choice depends on cirrhosis status, prior treatment, drug interactions, renal function and other clinical factors. AASLD/IDSA guidance recommends treatment for nearly all people with active HCV infection, except when a short life expectancy cannot be improved by HCV treatment, transplantation or another directed intervention.² Patients with decompensated cirrhosis require specialist assessment because protease-inhibitor-containing regimens are unsuitable.
Autoimmune hepatitis:
Treatment commonly involves immunosuppression, often corticosteroids with or without azathioprine. Treatment and tapering are individualized according to disease activity, response, adverse effects and relapse risk. Long-term monitoring is necessary.
Alcohol-associated liver disease:
Core management includes abstinence, treatment of alcohol use disorder, nutritional support, correction of deficiencies and management of complications. Patients at risk of withdrawal may require medically supervised withdrawal management.
MASLD:
Management includes weight reduction when appropriate, physical activity, diabetes and lipid management, cardiovascular risk reduction and assessment of fibrosis. Treatment should be tailored to metabolic risk and liver disease severity.
5. Liver cirrhosis
5.1 Definition and pathophysiology
Cirrhosis is advanced chronic liver disease characterized by diffuse fibrosis, regenerative nodules and distortion of hepatic architecture. It can cause:
1. Increased intrahepatic vascular resistance.
2. Portal hypertension.
3. Reduced hepatic synthetic and metabolic function.
4. Altered drug metabolism and detoxification.
5. Increased risk of HCC.
Common causes include chronic HBV or HCV, alcohol-associated liver disease, MASLD, autoimmune hepatitis, cholestatic disease and genetic/metabolic disorders such as hemochromatosis, Wilson disease and alpha-1 antitrypsin deficiency.
5.2 Compensated and decompensated cirrhosis
Compensated cirrhosis means the patient has not developed overt clinical decompensation such as ascites, variceal hemorrhage or hepatic encephalopathy. Compensated patients may nevertheless have clinically significant portal hypertension and remain at risk of progression.
Decompensated cirrhosis is characterized by development of complications, especially ascites, variceal bleeding or hepatic encephalopathy. Decompensation substantially changes prognosis and should prompt specialist evaluation, including consideration of transplant assessment where appropriate.⁴
5.3 Clinical manifestations
Early or compensated disease:
· Fatigue, weakness, reduced appetite or weight loss.
· Nonspecific abdominal discomfort.
· Few or no physical signs.
Portal hypertension:
· Splenomegaly and thrombocytopenia.
· Esophageal or gastric varices.
· Portosystemic collateral vessels.
· Ascites.
· Portal hypertensive gastropathy.
Variceal bleeding may present with hematemesis, melena, syncope, hypotension or shock and is a medical emergency.
Ascites:
Ascites causes increasing abdominal girth, discomfort, early satiety, weight gain, dyspnea or reduced mobility. Its formation involves portal hypertension, splanchnic vasodilation, renal sodium retention and altered effective circulating volume.
Hepatic encephalopathy:
This neuropsychiatric syndrome ranges from subtle attention or sleep changes to confusion, disorientation, asterixis and coma. Precipitating factors include infection, gastrointestinal bleeding, constipation, dehydration, electrolyte abnormalities and sedatives. Blood ammonia concentration alone does not establish or grade hepatic encephalopathy; clinical assessment and identification of precipitants are essential.
Other manifestations:
· Jaundice and pruritus.
· Peripheral edema.
· Spider angiomas and palmar erythema.
· Easy bruising.
· Sarcopenia and malnutrition.
· Gynecomastia, hypogonadism or reduced body hair.
· Glucose intolerance and osteoporosis.
Severe complications include spontaneous bacterial peritonitis (SBP), hepatorenal syndrome, hepatopulmonary syndrome, hepatic hydrothorax, acute-on-chronic liver failure and HCC.
5.4 Diagnostic evaluation
Laboratory evaluation commonly includes CBC, AST/ALT, bilirubin, albumin, PT/INR, creatinine and sodium. These tests help evaluate complications and prognosis but must be interpreted in context.
Ultrasound may show nodular liver morphology, altered liver size, splenomegaly, ascites or collateral vessels. Doppler ultrasound can assess portal venous flow. CT or MRI is used when indicated, including evaluation of focal lesions.
Fibrosis assessment may include transient elastography and validated serum scores such as FIB-4 or APRI. Results may be affected by inflammation, cholestasis and other factors and should not be interpreted in isolation.
Upper endoscopy is used for variceal assessment according to the patient’s risk and the selected portal-hypertension strategy.
Diagnostic paracentesis:
New-onset ascites in cirrhosis should undergo diagnostic paracentesis. Testing commonly includes cell count and differential, albumin, total protein and culture when infection is suspected. A serum-ascites albumin gradient (SAAG) of at least 1.1 g/dL supports portal hypertension as the cause. An ascitic polymorphonuclear leukocyte count of at least 250 cells/mm³ is the standard threshold for SBP diagnosis in the appropriate clinical setting.⁵
5.5 Severity assessment
Child–Pugh score:
Uses bilirubin, albumin, PT/INR, ascites and hepatic encephalopathy to classify severity as Child–Pugh A, B or C. It supports prognostic assessment but has limitations and should be interpreted clinically.
MELD/MELD-Na:
Uses laboratory variables including bilirubin, INR and creatinine, with sodium incorporated in MELD-Na. It helps estimate mortality risk and is used in transplant prioritization. Scores support, but do not replace, clinical judgment.
5.6 General principles of treatment
A. Treat the underlying cause
Use disease-directed treatment for HBV, HCV, autoimmune hepatitis, alcohol-associated disease, MASLD or other etiologies as appropriate. Avoid further hepatic injury and review medication safety.
B. Ascites
Management generally includes dietary sodium restriction, diuretics when appropriate, weight monitoring, renal function and electrolyte monitoring. Spironolactone and furosemide are commonly used, with dosing individualized according to blood pressure, renal function, sodium, potassium and response. Therapeutic paracentesis is used for tense or symptomatic ascites. Albumin is indicated in selected circumstances, including after large-volume paracentesis and in specified SBP or renal-risk settings; follow current guidance.⁵,⁶
C. Portal hypertension and varices
Prevention and treatment depend on portal-hypertension severity and variceal risk. Nonselective beta-blockers, including carvedilol in appropriate patients, and endoscopic variceal ligation are used in selected settings. Acute variceal hemorrhage requires emergency stabilization, vasoactive therapy, antibiotic prophylaxis and urgent endoscopic management.⁷
D. Hepatic encephalopathy
Identify and correct precipitating factors, including infection, bleeding, constipation, dehydration, electrolyte disturbances and sedatives. Lactulose is commonly used and titrated to approximately two to three soft bowel movements daily; excessive dosing can cause dehydration and electrolyte disturbance. Rifaximin is added for selected patients with recurrent or persistent encephalopathy.
E. Spontaneous bacterial peritonitis
Perform prompt diagnostic paracentesis when indicated, initiate appropriate antibiotics, assess renal function and use albumin in patients who meet clinical criteria. Secondary prophylaxis may be indicated after an episode; decisions depend on current guidance and patient factors.
F. Nutrition
Malnutrition and sarcopenia are common. Provide adequate energy and protein, avoid prolonged fasting, use frequent meals and consider a late-evening snack. Protein restriction is generally not recommended in hepatic encephalopathy because it can worsen muscle wasting and nutritional status.⁴
G. HCC surveillance
Eligible patients with cirrhosis should generally undergo HCC surveillance approximately every six months. AASLD recommends ultrasound plus AFP at six-month intervals for at-risk patients who would be candidates for HCC-directed treatment.⁸ Surveillance strategy should follow current guidance and individual circumstances.
H. Liver transplantation
Transplant evaluation may be appropriate for recurrent decompensation, refractory ascites, recurrent encephalopathy, hepatorenal syndrome, severe hepatic dysfunction or selected HCC. Eligibility requires specialist assessment.
6. Chronic pancreatitis
6.1 Definition
Chronic pancreatitis is a persistent fibroinflammatory disease of the pancreas characterized by irreversible structural changes and variable exocrine and endocrine dysfunction. It may cause pain, maldigestion, malnutrition and diabetes.
6.2 Etiology
Contributors include:
· Alcohol exposure.
· Tobacco smoking.
· Genetic susceptibility, including PRSS1, SPINK1, CFTR and CTRC variants.
· Recurrent acute pancreatitis.
· Pancreatic duct obstruction or structural abnormalities.
· Hypertriglyceridemia or hypercalcemia.
· Autoimmune pancreatitis.
· Idiopathic disease.
Alcohol and tobacco are important risk factors, but chronic pancreatitis may occur in patients without either exposure.
6.3 Pathogenesis
Repeated or persistent pancreatic injury activates inflammatory pathways and pancreatic stellate cells, promoting extracellular matrix deposition and fibrosis. Structural changes may include acinar loss, ductal distortion, calcifications and atrophy. These changes reduce digestive enzyme secretion and, in advanced disease, may impair insulin production.
6.4 Symptomatology
Pain:
· Epigastric pain, sometimes radiating to the back.
· Recurrent episodes or persistent discomfort.
· Pain associated with meals in some patients.
· Nausea, reduced appetite or food avoidance.
Pain severity varies and may not correlate directly with structural disease severity.
Exocrine pancreatic insufficiency:
Loss of digestive enzyme secretion can cause steatorrhea, bulky or foul-smelling stools, diarrhea, weight loss, fat-soluble vitamin deficiency and malnutrition. Steatorrhea reflects impaired fat digestion and absorption.
Endocrine insufficiency:
Pancreatic damage may cause pancreatogenic (type 3c) diabetes, with hyperglycemia, polyuria, polydipsia and weight loss. Glucose abnormalities may coexist with malnutrition and variable insulin deficiency.
Nutritional manifestations:
Weight loss, muscle wasting, vitamin deficiencies, osteopenia or osteoporosis may result from reduced intake, pain and maldigestion.
Jaundice:
May occur with distal common bile duct compression, pancreatic head inflammation, a stricture or another obstructing lesion. Persistent or progressive jaundice requires evaluation for biliary obstruction and pancreatic malignancy.
6.5 Physical examination
Findings may include epigastric tenderness, low body weight, muscle wasting, abdominal distension or signs of diabetes and nutritional deficiency. Examination can be relatively unremarkable despite substantial disease. A palpable mass, persistent jaundice or changing symptoms requires further investigation.
6.6 Diagnostic investigations
Laboratory:
· Glucose and HbA1c.
· Liver biochemical tests and bilirubin when biliary obstruction is possible.
· Lipase when acute pancreatitis is suspected.
· Nutritional assessment and fat-soluble vitamin testing when indicated.
Serum amylase and lipase can be normal in established chronic pancreatitis; normal values do not exclude the diagnosis.
Imaging:
· CT can identify calcifications, atrophy, ductal dilatation and complications.
· MRI/MRCP evaluates pancreatic parenchyma, duct anatomy, strictures and biliary abnormalities.
· Endoscopic ultrasound may help when the diagnosis remains uncertain or subtle changes require assessment.
The ACG guideline supports cross-sectional imaging as a central part of diagnostic evaluation, with endoscopic ultrasound and pancreatic function tests used as complementary tools.¹
Exocrine function:
Fecal elastase-1 is a commonly used noninvasive test when exocrine pancreatic insufficiency is suspected. A low result supports insufficiency in the appropriate clinical setting, but interpretation depends on stool consistency and other factors.
6.7 Differential diagnosis
Consider peptic ulcer disease, gallstone disease, biliary obstruction, pancreatic cancer, gastroesophageal reflux, functional gastrointestinal disorders and other causes of chronic abdominal pain. Chronic pancreatitis does not exclude pancreatic cancer. Progressive pain, unexplained weight loss, new-onset diabetes, persistent jaundice, a mass or progressive ductal obstruction warrants evaluation.
6.8 General principles of treatment
A. Alcohol abstinence and smoking cessation
Recommend abstinence from alcohol in alcohol-associated disease and cessation of tobacco. Offer support for substance-use treatment when needed.
B. Pain management
Treatment is individualized and may include nonopioid analgesics, selected adjuvant medications, endoscopic therapy for obstructive disease and surgery in selected patients. Long-term opioid therapy requires careful risk-benefit assessment and monitoring.
C. Pancreatic enzyme replacement therapy (PERT)
PERT is indicated for clinically significant exocrine pancreatic insufficiency. Preparations contain lipase, amylase and proteases and are taken with meals and snacks according to the prescribed regimen. The goal is to improve digestion, reduce steatorrhea and maintain nutrition. Enzyme replacement should not be presented as a universally effective treatment for pancreatic pain in the absence of exocrine insufficiency.
D. Nutrition
Provide adequate calories and protein, monitor weight and nutritional status, and correct deficiencies. Fat-soluble vitamins A, D, E and K may require supplementation. Severe fat restriction is not routinely necessary when PERT and nutritional management are adequate.
E. Diabetes
Monitor glucose and HbA1c and individualize treatment. Insulin may be required due to impaired pancreatic insulin secretion. Management should account for nutritional status and hypoglycemia risk.
F. Endoscopic treatment
May be considered for selected ductal stones, strictures, obstruction, symptomatic pseudocysts or biliary obstruction. Treatment depends on anatomy, symptoms and local expertise.
G. Surgery
Surgery may be considered for persistent disabling pain, ductal obstruction, complications, suspected malignancy or failure of appropriate medical/endoscopic management. Procedure selection depends on disease distribution and anatomy. Total pancreatectomy is not routine treatment; it is reserved for highly selected situations because it causes profound endocrine and exocrine consequences.¹
7. Comparative clinical features
Chronic hepatitis:
· Primary pathology: persistent hepatic inflammation.
· Typical symptoms: fatigue, anorexia, nausea, possible right upper-quadrant discomfort.
· Key assessment: etiology, liver injury, synthetic function and fibrosis.
· Major risks: progressive fibrosis, cirrhosis and HCC.
Cirrhosis:
· Primary pathology: fibrosis, regenerative nodules and architectural distortion.
· Typical symptoms: fatigue; in decompensation, ascites, jaundice, bleeding or encephalopathy.
· Key assessment: portal hypertension, synthetic function, renal function and complications.
· Major risks: variceal hemorrhage, SBP, encephalopathy, hepatorenal syndrome and HCC.
Chronic pancreatitis:
· Primary pathology: pancreatic fibrosis and structural damage.
· Typical symptoms: epigastric pain, maldigestion, weight loss and possible diabetes.
· Key assessment: pancreatic structure, exocrine function, nutrition and glucose metabolism.
· Major risks: exocrine insufficiency, diabetes, obstruction, pseudocyst and possible malignancy.
8. Differential diagnosis
Chronic hepatitis versus cirrhosis:
Both may cause fatigue, anorexia, jaundice or hepatomegaly. Cirrhosis is more strongly associated with portal hypertension, ascites, varices, splenomegaly, encephalopathy and impaired synthetic function. Clinical evaluation, laboratory testing, imaging and fibrosis assessment are needed; symptoms alone cannot reliably stage disease.
Cirrhosis versus chronic pancreatitis:
Both can cause abdominal discomfort, weight loss and nutritional deficiencies. Portal hypertension, ascites and encephalopathy favor cirrhosis. Steatorrhea, pancreatic duct changes and exocrine insufficiency favor chronic pancreatitis.
Chronic pancreatitis versus pancreatic cancer:
Symptoms overlap. Progressive pain, unexplained weight loss, persistent jaundice, new diabetes, a pancreatic mass or progressive duct obstruction requires investigation. A prior diagnosis of chronic pancreatitis should not delay malignancy evaluation when clinical features change.
9. Evidence-based clinical discussion
Etiological treatment is central:
Treatment should target the underlying cause rather than elevated aminotransferases alone. HBV therapy suppresses viral replication; HCV therapy can achieve cure; autoimmune hepatitis often requires immunosuppression; alcohol abstinence and metabolic risk management are important in relevant disease.
Cirrhosis care requires prevention and treatment of decompensation:
Management includes etiological therapy, portal-hypertension assessment, ascites care, prevention and treatment of variceal bleeding, recognition of encephalopathy, renal monitoring, nutrition and HCC surveillance. AASLD guidance emphasizes risk stratification and prevention of first or recurrent decompensation.⁷
Chronic pancreatitis requires multidisciplinary care:
Pain, maldigestion, nutritional impairment and diabetes may coexist. Established structural fibrosis is generally irreversible, so treatment focuses on risk-factor modification, symptom control, enzyme replacement when indicated, nutrition and complications.¹
Clinical recommendations vary by disease stage, comorbidity, regional resources and guideline updates. Specialist assessment is necessary for severe disease, complications, uncertain diagnosis or treatment failure.
10. Clinical relevance and red flags
Chronic hepatitis:
· Identify and treat the cause.
· Confirm active viral infection when suspected.
· Assess fibrosis and monitor progression.
· Avoid alcohol and unnecessary hepatotoxic agents.
· Review vaccination and transmission-prevention needs.
Cirrhosis:
· Determine compensated versus decompensated status.
· Assess portal hypertension and HCC surveillance eligibility.
· Evaluate new ascites promptly.
· Monitor renal function, electrolytes and nutrition.
· Assess encephalopathy and infection.
· Consider transplant referral when indicated.
Chronic pancreatitis:
· Assess alcohol and tobacco exposure.
· Evaluate persistent or changing pain.
· Assess exocrine insufficiency and nutrition.
· Monitor glucose.
· Use PERT when indicated.
· Investigate obstruction and possible malignancy.
Urgent medical assessment is required for hematemesis, melena, hypotension, rapidly increasing abdominal distension, fever with ascites, severe persistent abdominal pain, new confusion, reduced urine output or rapidly worsening jaundice.
11. Limitations
This is a narrative educational review, not a systematic review or meta-analysis. It did not use a formal reproducible search strategy across PubMed, Google Scholar or Cochrane Library, and it did not conduct independent screening, risk-of-bias assessment or evidence grading. It provides general principles rather than exhaustive drug doses or disease-specific algorithms. Clinical recommendations may change; actual treatment must be individualized and checked against current guidance.
12. Future Research Directions
Future research should address:
1. Earlier and more accurate identification of hepatic fibrosis.
2. Noninvasive prediction of disease progression.
3. Prevention of cirrhosis decompensation and improved transplant timing.
4. Long-term outcomes after viral hepatitis treatment.
5. Nutritional interventions in chronic liver disease.
6. Improved pain strategies in chronic pancreatitis.
7. Better treatment of pancreatic exocrine insufficiency.
8. Prevention and management of pancreatogenic diabetes.
9. Therapies that modify established pancreatic fibrosis.
10. Improved access to evidence-based treatment.
13. Conclusion
Chronic hepatitis, liver cirrhosis and chronic pancreatitis are important chronic digestive diseases that may cause inflammation, fibrosis, impaired organ function and systemic complications.
Chronic hepatitis may be asymptomatic or present with fatigue, anorexia, nausea, hepatomegaly, jaundice or biochemical abnormalities. Persistent injury can lead to fibrosis, cirrhosis and HCC. Treatment is cause-specific and includes antiviral therapy, immunosuppression or management of alcohol-associated and metabolic disease when appropriate.
Cirrhosis is characterized by fibrosis, regenerative nodules, portal hypertension and impaired hepatic function. Major complications include ascites, variceal hemorrhage, hepatic encephalopathy, SBP, renal dysfunction and HCC. Care includes treatment of the cause, prevention and management of complications, nutrition, surveillance and transplant evaluation when appropriate.
Chronic pancreatitis causes persistent pancreatic structural injury and may present with pain, steatorrhea, weight loss, malnutrition and diabetes. Treatment focuses on alcohol and tobacco cessation, individualized pain management, PERT for exocrine insufficiency, nutrition, glucose management and selected endoscopic or surgical interventions.
Across all three conditions, early diagnosis, etiological treatment, careful monitoring and timely management of complications are fundamental. This article is intended for medical education and is not a substitute for current clinical guidelines or specialist care.
14. References
1. Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol. 2020;115(3):322-39. doi:10.14309/ajg.0000000000000535. PMID:32022720.
2. Bhattacharya D, Aronsohn A, Price J, Lo Re V 3rd, Sulkowski M, et al. AASLD/IDSA 2023 Clinical Practice Guidance Update for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2023. doi:10.1093/cid/ciad319.
3. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024. ISBN: 978-92-4-009090-3.
4. Grady J. Back to Basics: Outpatient Management of Cirrhosis. AASLD Liver Fellow Network. 2024 Feb 15. Available from: https://www.aasld.org/liver-fellow-network
5. Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48. doi:10.1002/hep.31884. PMID:33942342.
6. Orman ES, Fortune BE, John BV, Asrani SK. AGA Clinical Practice Update on the management of ascites, volume overload, and hyponatremia in cirrhosis: expert review. Gastroenterology. 2025;169(7):1547-57. doi:10.1053/j.gastro.2025.08.029. PMID:41114681.
7. Kaplan DE, Ripoll C, Thiele M, Fortune BE, Simonetto DA, Garcia-Tsao G, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79(5):1180-211. doi:10.1097/HEP.0000000000000647. PMID:37870298.
8. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922-65. doi:10.1097/HEP.0000000000000466. PMID:37199193.
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502-83. doi:10.1016/j.jhep.2025.03.018. PMID:40348683.
10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315-74. doi:10.1016/j.jhep.2024.08.028. PMID:39690085.